Navigation Links
New Research Study Seeks Improved Quality of Life for People in the Future with Schizophrenia
Date:8/26/2008

Miranda Chakos, MD of SUNY Downstate Medical Center leads research for local patients

Brooklyn, NY (PRWEB) August 26, 2008 -- Imagine going through the day without the ability to concentrate and focus on the things you enjoy and important tasks that you need to complete. Think what it would be like, struggling to remember what you just talked about or learned a short time ago. Consider how you would feel if you couldn't even accomplish simple tasks, such as making a phone call, grocery shopping or scheduling an appointment.

We all have challenging moments . . . but for people suffering from schizophrenia, these frustrations are a way of life, virtually every day. People with schizophrenia struggle to concentrate, remember and learn. These deficits associated with the thinking process are called cognitive impairments, making it difficult to accomplish the demands of everyday life, both big and small.

Managing the demands of daily life is made easier when individuals with schizophrenia maintain a stable regimen of medication -- even more so for those with trusted family members or caregivers to help oversee the individual's personal affairs and coordinate care. Despite the challenges, most people with schizophrenia and their caregivers are searching for a better quality of life.

Fortunately, there is hope, thanks to a new https://www.cognitivestudy.com/whatToExpect.php [investigational drug research study] now underway in the Brooklyn, NY area. The primary goal of this study is to evaluate the safety and effectiveness of an investigational drug in improving cognitive functioning for people with schizophrenia, using a new evaluation tool called https://www.cognitivestudy.com/additionalResources.php [MATRICS] (Measurement and Treatment Research to Improve Cognition in Schizophrenia). This study is unique because participants are not required to change their already-stable medication regimen. Rather, the new investigational medication is added to their currently established treatment.

Candidates for this study must be 18 to 65 years old, diagnosed with schizophrenia at or before age 35 and currently taking one of five medications for schizophrenia which include olanzapine, risperidone/paliperidone, quetiapine or aripiprazole. Participants must also be considered outpatient (living in the community). https://www.cognitivestudy.com/faq.php [Qualified study participants] will receive all investigational medication and study-related care at no cost, and may also receive compensation for travel.

Miranda Chakos, MD of SUNY Downstate Medical Center seeks participants for this new study. If you or someone you know suffers from schizophrenia, please contact us for additional information at 888.988.6736. Further details about the study are also available at http://www.cognitivestudy.com.

Contact:
Hal Coxon
Axiom Accelerated Clinical Patient Recruitment
(847) 919-1005
halcoxon@axmarketing.com
http://www.cognitivestudy.com

# # #

Read the full story at http://www.prweb.com/releases/medical_study/schizophrenia/prweb1241444.htm


'/>"/>
Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved

Related medicine news :

1. Research finds Americas elderly suffering abuse
2. Operations research promises continued gains for HIV treatment in resource-limited countries
3. SNM and ASTRO team up to advance molecular imaging and cancer research
4. CytoViva(R) Introduces Breakthrough Nano-Technology Research Tool
5. The Brain Aneurysm Foundation Announces 2008 Research Grant Recipients
6. Reeve Foundation Recruits Distinguished Stem-Cell Neurobiologist - The Salk Institutes Samuel L. Pfaff, Ph.D. - to its International Research Consortium
7. UTMB researchers test new vaccine to fight multiple influenza strains
8. AIAM Sponsors Leading Child Safety Research Initiative
9. UNC researcher aims to unmask cancer cells to trigger bodys immune system
10. STEMCELL Technologies Introduces AggreWell™400 for Standardized Embryonic Stem Cell and Induced Pluripotent Stem Cell Research
11. UCSF faculty receive $13.7M from CIRM for stem cell research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2017)... ... July 21, 2017 , ... How physicians and athletic trainers ... say researchers presenting their work at the American Orthopaedic Society for Sports ... evaluating the patterns of change in concussion symptom presentation, diagnostic tools used and ...
(Date:7/20/2017)... ... 2017 , ... ChenMed , a leading provider of value-based care for ... as Richmond Chief Medical Officer. Dr. McCarter, formerly Associate Professor of Family ... of Ambulatory Services for the UVA Health System, brings 30 years of highly relevant ...
(Date:7/20/2017)... ... July 20, 2017 , ... ... IT operations analytics and application performance monitoring (APM) solutions, has expanded its ... services providers. , According to Peter Ohrenberger, sales director at Nastel, “We’ve ...
(Date:7/20/2017)... ... 20, 2017 , ... For individuals with extended hospital stays or who are ... such facilities are specially designed to accommodate patients with a wide range of ailments ... from Rochester, Ind., has invented the patent-pending PORTABLE ARM REST, a specially designed armrest ...
(Date:7/20/2017)... (PRWEB) , ... July 20, 2017 , ... Team Type ... access to medicine for everyone affected by diabetes, is teaming up with a Microsoft ... global event kicks off on July 24th. , “Team Type 1’s mission overlaps ...
Breaking Medicine News(10 mins):
(Date:7/11/2017)...  Dr. Echenberg, founder of Echenberg Institute, is announcing a new safe ... from painful intercourse and other painful pelvic pain conditions such as pelvic ... ... ... Florida -based start-up company, VuVatech LLC, fills a void in the ...
(Date:7/10/2017)... GAITHERSBURG, Md. , July 10, 2017 ... in non-animal test methods, is the recipient of a ... by the PETA International Science Consortium. The device, which ... be used to expose human lung cells to airborne ... lung. IIVS will use the VITROCELL® system for testing ...
(Date:7/10/2017)... , July 10, 2017 Locus Biosciences ... Note to support the development of CRISPR-Cas3 antimicrobial therapeutics. ... Limited, a leading Chinese Internet services provider, and joined ... advance multiple infectious disease product programs targeting antibiotic resistant ... Founded by Dr. Rodolphe Barrangou ...
Breaking Medicine Technology: